• In the past week, STERIS reported a quarterly update showing 9.9% year-on-year revenue growth, ahead of analyst expectations, alongside EBIT margin expansion to 23.1% and strong free cash flow generation.
• The results underscored the importance of STERIS’s recurring infection-prevention services and consumables, which, together with a sizeable healthcare capital backlog, enhanced visibility into future operating performance.
• Now we’ll consider how this margin expansion, driven by pricing and higher service volumes, may influence STERIS’s existing investment narrative.

AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

STERIS Investment Narrative Recap

To own STERIS, you have to believe in the durability of its infection prevention role and the value of its recurring services and consumables. The latest quarter’s margin expansion and free cash flow support this thesis, but do not materially change the near term focus on executing the growing healthcare capital backlog or the risk that reimbursement and tariff pressures could compress margins if pricing power weakens.

Among recent announcements, the fiscal 2026 outlook for high single digit reported revenue growth stands out alongside this quarter’s 23.1% EBIT margin. Together, they frame the key catalyst around sustained growth in higher margin services and consumables, helped by a sizeable healthcare capital backlog, while investors continue to weigh the impact of cost inflation and regulatory scrutiny on future profitability.

Yet beneath the solid quarter, investors should be aware of how rising tariffs and reimbursement pressure could...

STERIS' narrative projects $6.8 billion revenue and $1.0 billion earnings by 2028. This requires 6.8% yearly revenue growth and roughly a $352 million earnings increase from $647.7 million today.

Uncover how STERIS' forecasts yield a $281.62 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$230 to US$288 per share, showing how far individual views can stretch. When you set this against STERIS’s recent margin expansion driven by pricing and higher service volumes, it underlines why you may want to examine several perspectives on how sustainable that profitability really is.

Explore 3 other fair value estimates on STERIS - why the stock might be worth as much as 7% more than the current price!

Build Your Own STERIS Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your STERIS research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free STERIS research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate STERIS' overall financial health at a glance.

Ready For A Different Approach?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.